Gesynta Pharma’s GS-248 Wins FDA Orphan Drug Designation

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Gesynta Pharma’s GS-248, its oral therapy for people with systemic sclerosis (scleroderma). Orphan drug status aims to encourage therapies for rare diseases through benefits such as seven years of market exclusivity and exemption from FDA fees. “The orphan drug designation granted to our drug candidate GS-248

Click here to continue reading.